Crinetics Pharmaceuticals

New York City, we're coming your way! Join us on August 8 for an Everyday Advocacy event designed to bring people living with acromegaly and their care partners together. Through meaningful conversations and shared experiences, you'll have the opportunity to strengthen your self-advocacy skills, learn from others, and connect with a supportive community. Whether you're just beginning your advocacy journey or looking to continue growing, we'd love to have you with us. 🗓️ August 8 📍 New York City, NY 🔗 crinetics.com/ea-events/ #EverydayAdvocacy #Acromegaly

Join us on August 1 in Orlando for a small but powerful Everyday Advocacy workshop for people living with acromegaly and their care partners. This intimate session is designed to help you strengthen your voice, build confidence in self-advocacy, and connect with others who truly get it; all while gaining practical tools you can take with you. Space is limited to keep it meaningful, secure your spot early. 🗓️ August 1 📍 Orlando, FL 🔗 Register here: lnkd.in/gcfRUpp6 #EverydayAdvocacy #Acromegaly

Today we announced an agreement that @VertexPharma will acquire Crinetics. This deal adds strengths in the areas of R&D and commercialization to bring more potentially best-in-class medicines to patients with serious diseases. crinetics.com/press-releases…

Yesterday, the Crinetics team had the opportunity to watch an early cut of Overlooked, a documentary by CAH patient and advocate Abram Iman. We're grateful to Abram for sharing his story and for his commitment to raising awareness of the CAH patient experience. #CAH

This week, members of the Crinetics team are attending #BIO2026 here in our hometown of San Diego. We're looking forward to connecting with partners, investors, and colleagues who share our commitment to advancing science for patients. #BIOConvention #Biotech #Endocrinology

Finding the right care for an endocrine condition can be a long road. From navigating specialists to waiting years for answers, many patients face real challenges before they even have a diagnosis. That’s why we created Everyday Advocacy, a resource designed to support patients living with endocrine conditions. Learn more: everydayadvocacy.com

#ENDO2026 is a wrap for the Crinetics team. It was a productive few days, new data presented, meaningful conversations had, and important connections made with the endocrine community.

Join us today at 12:30pm CT for our product theater on acromegaly management featuring Dr. Anthony Heaney and a person living with acromegaly. Advancing Acromegaly Management: Bridging Clinical Evidence and the Patient Journey with PALSONIFYTM (paltusotine) 📅 June 15 | 12:30 PM #ENDO2026

Join us today at #ENDO2026 for a presentation of full Phase 2 trial results of atumelnant congenital adrenal hyperplasia. Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia 📅 June 15 | 12:00 PM 📍 ENDO Expo Hall, McCormick Place West

Findings from a real-world analysis of biochemical control in acromegaly will be presented today at #ENDO2026. Real-World IGF-1 Control in Acromegaly: Insights from US Claims and Laboratory Data 📅 June 15 | 12:00 PM 📍 ENDO Expo Hall, McCormick Place West

Join us today at 12:30pm CT for our product theater on acromegaly management featuring Dr. Anthony Heaney and a person living with acromegaly. Advancing Acromegaly Management: Bridging Clinical Evidence and the Patient Journey with PALSONIFY (paltusotine) 📅 June 15 | 12:30 PM #ENDO2026

Findings from a real-world analysis of biochemical control in acromegaly will be presented today at #ENDO2026. Real-World IGF-1 Control in Acromegaly: Insights from US Claims and Laboratory Data 📅 June 15 | 12:00 PM 📍 ENDO Expo Hall, McCormick Place West

Join us today at #ENDO2026 for a presentation of full Phase 2 trial results of atumelnant congenital adrenal hyperplasia. Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia 📅 June 15 | 12:00 PM 📍 ENDO Expo Hall, McCormick Place West

Day 3 at #ENDO2026. Find us at the presentations below: Real-World IGF-I Control in Acromegaly: Insights from US Claims and Laboratory Data 📅 June 15; 12:00 PM 📍 ENDO Expo Hall, McCormick Place West Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia 📅 June 15 | 12:00 PM 📍 ENDO Expo Hall, McCormick Place West Advancing Acromegaly Management: Bridging Clinical Evidence and the Patient Journey with PALSONIFYTM (paltusotine) 📅 June 15 | 12:30 PM 📍 ENDOExpo; Theater 1

An oral presentation on atumelnant in ACTH-dependent Cushing syndrome is on the schedule today at #ENDO2026. Add it to yours! ‘Block And Replace’ Atumelnant (CRN04894) And Physiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In ACTH-dependent Cushing Syndrome 📅 June 14 | 3:45 PM 📍 Room W187

Data from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies will be presented at #ENDO2026. See below for presentation details: 📅 June 14 | 2:30pm CT 📍 Room W183BC #ENDO2026

Data from our research on once daily atumelnant (CRN04894) in adults with congenital adrenal hyperplasia will be presented today at #ENDO2026. Details below: Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses With Sustained Androgen Reduction in Adults With Congenital Adrenal Hyperplasia 📅 June 14 | 2:10 PM 📍 Room W184ABC #CAH #CongenitalAdrenalHyperplasia #ENDO2026

Join us today at 1:45pm CT to learn more about our model-informed dose selection data for atumelnant (CRN04894) ahead of a Phase 3 study in adults with classic congenital adrenal hyperplasia. This work reflects our commitment to rigorous, patient-centered drug development in CAH. Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia 📅 June 14 | 1:45 PM 📍 Room W184ABC

We're live at #ENDO2026. Today is a big day for the Crinetics team, with multiple presentations sharing new data across acromegaly and congenital adrenal hyperplasia. Here's where to find us: 🔬 Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in Combination With Cabergoline for the Treatment of Patients With Acromegaly 📅 June 14 | 12:00pm CT 📍 ENDO Expo Hall, McCormick Place West Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia 📅 June 14 | 1:45 PM 📍 Room W184ABC Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses With Sustained Androgen Reduction in Adults With Congenital Adrenal Hyperplasia 📅 June 14 | 2:10 PM 📍 Room W184ABC Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies 📅 June 14 | 2:30pm CT 📍 Room W183BC ‘Block And Replace’ Atumelnant (CRN04894) And Physiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In ACTH-dependent Cushing Syndrome 📅 June 14 | 3:45 PM 📍 Room W187 Follow along for more updates today. #Endocrinology #Acromegaly #CAH